



## **Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2008**

January 31, 2008

-- Podcast to be Available Following Conference Call --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2008--Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. EST on Thursday, February 7, 2008 to discuss the company's financial results for its third quarter of fiscal 2008. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes' website at [www.alkermes.com](http://www.alkermes.com) or may be accessed by dialing 1-866-814-8476 for domestic callers and 1-703-639-1370 for international callers. The conference call ID number is 1190768.

A replay of the conference call will be available from 7:30 p.m. EST on Thursday, February 7, 2008 through 5:00 p.m. EST on Wednesday, February 13, 2008, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 1190768. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Wednesday, February 13, 2008.

Alkermes, Inc. is a biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease. Alkermes manufactures RISPARDAL(R) CONSTA(R), marketed by Janssen-Cilag (Janssen, L.P.), a wholly owned division of Johnson & Johnson, and developed and manufactures VIVITROL(R), marketed in the U.S. primarily by Cephalon, Inc. The company's pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Alkermes is headquartered in Cambridge, Massachusetts, with research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.  
Debra Koufos, 617-583-6220  
Associate, Corporate Communications

SOURCE: Alkermes, Inc.